<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620460</url>
  </required_header>
  <id_info>
    <org_study_id>2020-TX-006</org_study_id>
    <nct_id>NCT04620460</nct_id>
  </id_info>
  <brief_title>Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia</brief_title>
  <official_title>Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on our research background, we hypothesize that LIFUS has neuromodulation effects on&#xD;
      brain cortex and the active LIFUS on left-DLPFC would improve negative symptoms in&#xD;
      schizophrenia patients. It would firstly verify the safety of LIFUS on human as well. The&#xD;
      multimodal MRI will be contributed to investigate the possible mechanism of negative&#xD;
      symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firstly, we plan to explore the short-term effects of LIFUS on cortical excitability by&#xD;
      detecting the MEP amplitude. 40 patients and relatively well matched healthy-control would be&#xD;
      enrolled. After MEP detection and baseline evaluations, the two groups will be treated with&#xD;
      one-single intervention on the primary motor cortex. The cognitive function and MEP amplitude&#xD;
      will be assessed respectively at the moment, after 15 minutes and 30 minutes. Then, it is a&#xD;
      randomized double-blind sham-controlled LIFUS intervention trial in schizophrenia patients.&#xD;
      After screening and baseline evaluations, the 40 patients with schizophrenia will be treated&#xD;
      with active LIFUS or sham stimulation for 3 weeks on the left DLPFC. The multimodal MRI will&#xD;
      be acquired. Clinical symptoms and cognitive function will be assessed respectively at&#xD;
      baseline, at the end of fifth treatments and after the end of the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Symptoms-PANSS</measure>
    <time_frame>baseline and 15 days</time_frame>
    <description>Change from baseline in Positive and Negative Syndrome Scale(PANSS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Symptoms-SANS</measure>
    <time_frame>baseline and 15 days</time_frame>
    <description>Change from baseline in the Scale for the Assessment of Negative Symptoms(SANS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function</measure>
    <time_frame>baseline, after the fifth treatment and 15 days</time_frame>
    <description>Change from baseline in the Brief Cognition Test (C-BCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of brain neuroimaging</measure>
    <time_frame>baseline, fifth treatment and 15th treatment</time_frame>
    <description>Brain structure, Resting-state fMRI data, Arterial Spin Labeling(ASL), 1H-MRS in DLPFC are acquired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortex Excitability</measure>
    <time_frame>baseline，the moment after the intervention, after 15 minutes and 30 minutes</time_frame>
    <description>MEP amplitude</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Negative Symptoms of Schizophrenia</condition>
  <arm_group>
    <arm_group_label>LIFUS-left DLPFC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients will be treated with active LIFUS for 3 weeks on the left DLPFC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIFUS-SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>20 patients will be treated with sham LIFUS for 3 weeks on the left DLPFC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low-intensity Focused Ultrasound(LIFUS)</intervention_name>
    <description>Patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC.</description>
    <arm_group_label>LIFUS-SHAM</arm_group_label>
    <arm_group_label>LIFUS-left DLPFC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria (patients):&#xD;
&#xD;
               1. Meet the DSM-5 diagnostic criteria for schizophrenia or schizoaffective disorder;&#xD;
&#xD;
               2. Age18-50, right-handed, Han nationality;&#xD;
&#xD;
               3. the score of at least 1 item from N1 to N7 is ≥4 (moderate or above);&#xD;
&#xD;
               4. Be in a stable condition, received second-generation antipsychotics for at least&#xD;
                  4 weeks or more;&#xD;
&#xD;
               5. Written informed consent;&#xD;
&#xD;
          -  Exclusion Criteria (patients):&#xD;
&#xD;
               1. Current or past neurological illness, severe physical diseases, substance abuse&#xD;
                  or alcohol dependence, mental retardation, pregnant or lactation;&#xD;
&#xD;
               2. Uncooperative or risky patients with high excitement, stupor, disorder of words&#xD;
                  and deeds, negative suicide, etc.;&#xD;
&#xD;
               3. A history of MECT or other physical therapy within 6 months;&#xD;
&#xD;
               4. A history of epilepsy, or epileptic waves on the baseline EEG;&#xD;
&#xD;
               5. Ruled out share antiepileptic drugs, carbamazepine, valproic acid salt) or larger&#xD;
                  doses of benzodiazepines drugs (&gt; 10 mg/day, diazepam clonazepam 2 mg/day, 1&#xD;
                  mg/day, alprazolam lorazepam 2 mg/day, midazolam 10 mg/day, 20 mg/day, Mr Shah&#xD;
                  diazepam triazolam 0.5 mg/day), avoid the use of chlorine drug, (in principle, to&#xD;
                  avoid the use of antiepileptic drugs and clonazepam;Other antipsychotic drugs, if&#xD;
                  necessary, remain unchanged during the course of treatment;&#xD;
&#xD;
               6. Contraindications to LIFUS and MRI are present.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dengtang LIU</last_name>
    <phone>18017311138</phone>
    <phone_ext>86</phone_ext>
    <email>erliu110@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiong Xiang</last_name>
    <phone>13817369060</phone>
    <email>xiangqiongxl@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dengtang LIU</last_name>
      <phone>18017311138</phone>
      <email>erliu110@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>Dengtang LIU</investigator_full_name>
    <investigator_title>Chief Psychiatrist and Professor</investigator_title>
  </responsible_party>
  <keyword>Low-intensity Focused Ultrasound</keyword>
  <keyword>Negative Symptoms of Schizophrenia Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

